evidence; may consider switching to an IL-12/23i biologic if the patient has contraindications to TNFi biologics, including congestive heart failure, previous serious infections, recurrent infections, or demyelinating disease, or prefers less frequent drug administration. 18. Switch to an IL-12/23i biologic over switching to an IL-17i biologic (PICO 60) Moderate ( 50 Strong recommendation supported by moderate-quality evidence showing IL-12/23i biologic is effective for IBD while an IL-17i